Posted: 30 September 2021 Amplia Therapeutics and The Garvan have released a scientific paper today, revealing breakthrough research that lowers pancreatic cancer’s resistance to chemotherapy by ‘priming’ cancer cells. The breakthrough Amplia is pleased to report the publication of a key…
Posted 29 September 2021 The world’s first four-dimensional visual insight into the residual effects of COVID-19 or ‘long COVID’ providing an unprecedented ability for patients, clinicians and researchers to understand the ongoing impact of this disease has been…
Posted 29 September 2021 BioMelbourne Network member Cancer Therapeutics (CTx CRC Ltd) has unveiled its new name and brand identity – Canthera Discovery. This transformation forms part of a wider organisational strategy to continue the incredible legacy of…
Posted 27 September 2021 Highlights DCGI review complete and study formally recommended for regulatory approval Multiple clinical sites in India initiated Study protocol to recruit 600 participants with COVID-19 overall, with a safety analysis conducted after the first…
Posted 22 September 2021 AdAlta granted A$4.0m non-dilutive R&D Rebate funding Facility with Invest Victoria. Facility is one of the first of its kind from Victorian Government. Facility relates to FY2022 R&D and is in addition to existing…
Posted 15 September 2021 See BioMelbourne Network’s submission in response to the Australian Patent Box See Joint Statement on Patent Box Australia’s health innovators support the introduction of a Patent Box, and we welcome this initiative by the…
Posted: 10 September 2021 MedTechVic will bring people with disabilities together with world-leading technology and expertise to create life-changing new medical and enabling technologies. MedTechVic will create the Australian Assistive Technology Living Facility (LivingAT) on Swinburne’s Hawthorn campus,…
Posted 1 September 2021 SYNthesis Research has announced that Dr Martine Keenan will be joining as Chief Innovation Officer. Martine brings to the role exceptional national and international experience in translational drug discovery & development, and the reputation…
Posted 1 September 2021 Asthma Australia and BioMelbourne Network member 4DMedical have announced a partnership recognising a mutual commitment to promote awareness and improve diagnostic technology for 2.7 million people living with asthma. Asthma is a life-long respiratory…
Posted 1 September 2021 Neo-Bionica, a joint venture between Bionics Institute and The University of Melbourne has announced the appointment of two extremely well credentialled individuals. Dr Ludovic Labat has been appointed as CEO while BioMelbourne Network’s own Lusia Guthrie has…
Posted 29 August 2021 BioMelbourne Network member Oncology One has announced a new partnership with Children’s Cancer Institute to develop new drugs for the treatment of childhood solid tumours. The partnership is focused on the development of novel…
Industry survey in partnership between Global Victoria and BioMelbourne Network An opportunity for you to engage and take a short survey to inform our work on a critical issue to the Healthtech Industry Keep informed about the Issues…